#1 Clinical Trials Search in Europe

A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

3 1 1 1

What is this study about?

The study involves adults who have type 2 diabetes mellitus, a condition where the body does not use insulin properly, leading to high blood sugar. Participants will receive either the experimental tablet elecoglipron or the already approved oral medication semaglutide, both taken by mouth. The goal is to see how well each medicine controls blood sugar and affects body weight.

The purpose of the study is to compare the effectiveness of the two drugs for lowering blood sugar levels, measured by HbA1c, a lab test that shows average blood sugar over the past few months. Adults will be assigned to one of the two treatment groups and will take the assigned tablet each day for about one year. During this time, they will have regular clinic visits for simple checks such as blood draws and weight measurements, allowing researchers to track changes in blood sugar control and weight without any invasive procedures.

1 randomization

after joining the study you will be randomly assigned to receive either the test medication elecoglipron or the comparator medication semaglutide (brand name rybelsus). the assignment is made by the study team and you will not choose the group.

2 baseline assessments

before starting any medication you will have a series of baseline measurements. these include a blood test to determine your hbA1c level (a measure of average blood sugar), a measurement of your body weight, and a review of your medical history related to type 2 diabetes mellitus.

3 start of study medication

once randomization is complete you will begin taking the assigned tablet each day. the comparator tablets contain semaglutide and are available in strengths of 1.5 mg, 4 mg, and 9 mg; the exact dose you receive will follow the study dosing schedule. the test tablets contain elecoglipron; the specific dose is listed as 00 mg in the study documentation and will be administered as directed by the study protocol. all tablets are taken by mouth.

4 regular monitoring visits

throughout the 52‑week treatment period you will attend scheduled visits to check your safety and how well the medication is working. during each visit the study staff will repeat the hbA1c test, measure your body weight, and ask about any side effects or other health changes.

5 mid‑study assessments

at the middle of the study (around week 26) additional assessments may be performed to further evaluate blood sugar control and weight changes. these assessments follow the same procedures as the baseline and regular visits.

6 final assessment at week 52

at the end of week 52 you will undergo the final set of measurements. this includes a blood test for hbA1c, a measurement of body weight, and a summary of any adverse events experienced during the study. the results will be used to determine the effectiveness of the study medication compared with semaglutide.

7 study completion

after the week‑52 visit you will stop taking the study medication. the study team will provide instructions for any follow‑up care and will inform you about the overall study findings when they become available.

Who Can Join the Study?

  • Be diagnosed with type 2 diabetes mellitus (a condition that raises blood sugar) for at least 90 days before the screening visit.
  • Have diabetes that is not well controlled by diet, exercise, or up to two oral medicines that lower blood sugar.
  • Have a blood test called HbA1c that shows a level of 7% or higher but not more than 10.5% (this test measures average blood sugar over the past 2‑3 months).
  • Have a higher chance of heart problems, defined as having at least one of the following: proven coronary heart disease (narrowed heart arteries), peripheral arterial disease (narrowed arteries in the legs), ischemic cerebrovascular disease (reduced blood flow to the brain), or heart failure classified as NYHA class II‑III (moderate symptoms). Alternatively, having two or more risk factors for heart disease also qualifies.
  • Have a body mass index (BMI)</b) of 23 kg/m² or higher at the screening visit (BMI is a measure of body weight relative to height).
  • Have a stable body weight (no major weight loss or gain) for at least 90 days before screening, as reported by yourself or shown in medical records.

Who Cannot Join the Study?

  • Having type 1 diabetes mellitus, secondary forms of diabetes (including those present from birth), or a past episode of diabetic ketoacidosis (a dangerous condition where blood sugar is very high and creates acid) or hyperosmolar coma (extremely high blood sugar leading to loss of consciousness).
  • Currently receiving or planning to receive treatment for diabetic retinopathy (damage to the eye’s blood vessels caused by diabetes) or macular edema (swelling in the central part of the retina).
  • Having had more than one episode of severe hypoglycemia (dangerously low blood sugar) in the 180 days before screening, or a history of hypoglycemia unawareness (not feeling the warning signs of low blood sugar) or poor recognition of low‑sugar symptoms.
  • Having a clinically important condition that affects the upper gastrointestinal (GI) tract (the stomach and upper intestine), or regularly using any medication that changes gastric motility (how the stomach moves food) or gastric emptying (how quickly the stomach empties its contents).
  • Having a history of acute (sudden) or chronic (long‑term) pancreatitis (inflammation of the pancreas).
  • Having severe congestive heart failure classified as NYHA class IV (the most advanced stage where symptoms occur even at rest).
  • Having a personal or family history of medullary thyroid cancer (a specific type of thyroid cancer) or multiple endocrine neoplasia type 2 (an inherited condition that causes tumors in several hormone‑producing glands).

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Diabetes-Zentrum-Wilhelmsburg GbR Hamburg Germany
Gyncentrum Sp. z o.o. Katowice Poland
Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A. Lodz Poland
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Acibadem City Clinic Diagnostic And Consultation Center Tokuda EAD Sofia Bulgaria
Diabeteszentrum Hamburg West Hamburg Germany

Other Sites

Site Name City Country Status
Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o. Poznan Poland
Ospedale San Raffaele S.r.l. Milan Italy
Azienda Ospedaliero Universitaria Di Modena Modena Italy
Azienda Universitaria Ospedaliera Consorziale Policlinico Bari Bari Italy
Dfkvfqfykcsczao Dmedcvyx Mablz Duisburg Germany
Idjpmfpu fiqp Dalfusfsguiajypib Mlpueooj Gtqu Munster Germany
Utynespbxihqfhddkkglt Erujlogl Are Erlangen Germany
Kyoseqrd Cfnctwdr gzgvy Chemnitz Germany
Zyaxsqe fwqj kusahihrp Shfhkke Smqadooegwpcpdt Goxk Elsterwerda Germany
Hzyu Uds Dnlwavlzznbebxw Nvd Bwa Ovhgaavbhm Ufhflsaxcbdscjwfyrq Dvx Rszqqujvugpygapjr Bpxjgw Bad Oeynhausen Germany
Rbbdja Itjfrsrb fxhv mzdskzgcemtb Sanfevp uyq Ffzziliohlb Ghxc Oldenburg In Holstein Germany
Mfxkcdeidohmx Vpnnnihrnnpflvhvbd Au Bygrrpq Spebman Gzv Berlin Germany
Hsarkksyuzjndsy Bfzjftitw Gladbeck Germany
Zypoxhz fcy Kupyzigld Skuquzt Gchd St. Ingbert Germany
Pqdtwwpdnsojvmtlvb Dxpmg Damme Germany
Zjspatj fat Kochxpchv Ftcomerqa Aifpsa Oeascggsleon Wangen Germany
dscesswglqdrzcbwycsfh Zag Dym Jjws Ljtefeig Falkensee Germany
Uasnrgljfk Ox Dnlppuzw Debrecen Hungary
Odntct Enqrhlcmwtblr Cqixsar Kpwh Dunaújváros Hungary
Cntviang Krhi Budapest Hungary
Zhgx Mwgjml Scqts Rvfnay Kmntpl Zalaegerszeg Hungary
Ujqfbpgptm Ow Smvgkp Szeged Hungary
Jcpcjpsuzxnvxotelnzg Vynvawqcn Hthycpf Gfyq Kwhbolzcgpglngshglcbr Szolnok Hungary
Nhbnqt Vttdlizhd Somau Lnisx Kelpxk Salgotarjan Hungary
Mvuqjsay Kqap Budapest Hungary
Cljegyx Mrujmmhf Dylcxobpd Radom Poland
Ezgvor Sxq z onzb Lublin Poland
Pjhkrpudg Ioyyjjqe Mqyrsabj Mkdkxqdqizcn Sowcv Wfwzfblimrjm I Auzylrrlfrzse Warsaw Poland
Csvouflvs Dcwooqe Nzscd Sal kx Bialystok Poland
Mkibtnox Coyssiv Dqxsehxapdxitjneksohwxjzspufhxdeohuflqziwzqfqc Dcgwetkxyxdcb Slm z opex Cracow Poland
Mskksed Checwq Bkueliyy Llxd Yambol Bulgaria
Asxypqg Oowviwcasgf Uwxlkypkqjswg Fyrnzlra Iq Do Nybdam Naples Italy
Azzcsaq Uuauw Skcgnbedl Loqshq Dh Brzzfyl Bologna Italy
Clsugs Coktdvpquzic Mffrtjt Ssxdzc Milan Italy
Uetctztdhn Diwns Sonrv Dh Roli Lo Sencxqqv Rome Italy
Udorrkqega Mqfphidfqavp Hvhxqrst Frn Altahn Tkqpcward Kyriqdz Eubn Plovdiv Bulgaria
Cqgv &imuhjk Cwwqho fuq Axkmtktl Sdlhqpn ajf Tijpbjhqnj dl Cgjywy Chieti Italy
Mwrltpz Apxm Mqwaxnv Dvjugg Cogcbc Evzb Sofia Bulgaria
Geqhdblizglhfvwdpnf Dsz Ttstzgeku / Dod Bxeebbj Leipzig Germany
Doktwcfunsiadpc Squuixbechgtcbvej Prfht Pirna Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Bulgaria Bulgaria
Recruiting
06.07.2026
Germany Germany
Recruiting
06.07.2026
Hungary Hungary
Not yet recruiting
06.07.2026
Italy Italy
Not yet recruiting
06.07.2026
Poland Poland
Not yet recruiting
06.07.2026

Trial locations

Investigated Drugs:

Semaglutide (Rybelsus) is a medication taken by mouth that is already approved for treating type 2 diabetes. In this study it is used as the standard treatment, or “comparator,” so researchers can see how well the new drug works compared to a medicine that doctors already know is effective. Participants will take semaglutide tablets during the trial, and the researchers will measure how it controls blood sugar and any side effects.

Elecoglipron is the experimental drug being tested in this trial. It is also taken by mouth as a film‑coated tablet. The study is looking at whether elecoglipron can lower blood sugar, be safe to use, and be tolerated well by people with type 2 diabetes. Participants receiving elecoglipron will be compared to those taking the standard semaglutide tablets to see if the new drug works better, the same, or worse.

Investigated Diseases:

type 2 diabetes mellitus – Type 2 diabetes mellitus is a chronic condition where the body does not use insulin properly, leading to high blood sugar. Over time, the pancreas may produce less insulin, causing glucose levels to rise further. The condition often develops slowly and may start with mild symptoms such as increased thirst and frequent urination. As it progresses, blood sugar may remain elevated between meals and after fasting. The ongoing excess sugar can affect many organs and may lead to changes in vision, nerve function, and circulation.

Trial ID:
2025-523933-24-00
Protocol code:
D7261C00005
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

    Recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Czechia Germany Poland

  • A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia Denmark Germany Greece Hungary Poland +1